A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.